Core Insights - The article discusses the emerging opportunities in the children's height enhancement market, which has been largely dominated by growth hormones, highlighting the potential for new entrants like Akif to capture a share of the market [1][2]. Market Overview - The current height enhancement market primarily focuses on children below the P3 height percentile, which corresponds to the shortest 3 out of 100 children [2]. - There is a growing demand from non-short stature children (above P3) who wish to increase their height for better life opportunities, indicating a shift in consumer needs [2]. Product Insights - Akif's core product, "IGF-1 Growth Factor Sensitizer," aims to enhance children's sensitivity to growth factors through dietary supplementation, providing a scientific and safe approach to height enhancement [2][4]. - The product operates on the GH-IGF-1 axis, promoting growth by increasing the expression of IGF-1 and enhancing the sensitivity of growth plate cartilage cells [4]. Clinical Research and Development - Akif has initiated six clinical studies in China to validate the efficacy of the "IGF-1 Growth Factor Sensitizer," targeting various growth-related conditions in children [4][5]. - The company emphasizes the importance of clinical data to differentiate its product from ineffective alternatives in the market [4]. Marketing Strategy - Akif's marketing strategy has focused on organic growth through word-of-mouth and user education rather than traditional advertising, leveraging the unmet demand in the market [5][6]. - The company aims to establish a clear height management philosophy among parents, promoting the idea of using Akif's product for children above the P3 height threshold [6]. Expansion Plans - China is identified as a key market for Akif, with plans to expand into Japan, South Korea, and Southeast Asia by 2025, capitalizing on the strong demand for height enhancement in these regions [6]. - The acceptance of dietary supplements in these markets is notably higher, with consumers more willing to explore innovative solutions for height enhancement [6]. Research and Development Platform - Akif has established a drug screening platform based on primary cells, which allows for the development of various dietary supplement formulations, including over 50 different recipes [6]. - The platform supports research into complex health issues, enabling the company to innovate beyond height enhancement products to address other health concerns in children [6].
瞄准大众“追高”需求，「阿基孚」开发口服助长的“IGF-1增敏剂”，｜项目报道
3 6 Ke·2025-06-26 09:33